Article
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2018
Beshiri Michael L, Tice Caitlin M, Tran Crystal, Nguyen Holly M, Sowalsky Adam G, Agarwal Supreet, Jansson Keith H, Yang Qi, McGowen Kerry M, Yin JuanJuan, Alilin Aian Neil, Karzai Fatima H, Dahut William L, Corey Eva, Kelly Kathleen
Abstract excerpt
Purpose: Prostate cancer translational research has been hampered by the lack of comprehensive and tractable models that represent the genomic landscape of clinical disease. Metastatic castrate-resistant prostate cancer (mCRPC) patient-derived xenografts (PDXs) recapitulate the genetic and phenotypic diversity of the disease. We sought to establish a representative, preclinical platform of PDX-derived organoids...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.